Clinical trial · no report yet · Phase 3
NCT04566328
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- NCT04566328 ↗
- Recruiting
- ECOG-ACRIN Cancer Research Group
- 223 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 223 |
The trial
ClinicalTrials.gov- Official title
- Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Plasma Cell Myeloma; RISS Stage I Plasma Cell Myeloma; RISS Stage II Plasma Cell Myeloma
- Interventions
- Bortezomib; Daratumumab and Hyaluronidase-fihj; Dexamethasone; Lenalidomide; Quality-of-Life Assessment
- Arms
- Arm A (daratumumab, lenalidomide, dexamethasone) · Active comparator
- Arm B (bortezomib, daratumumab, lenalidomide, dexamethasone) · Experimental
- Arm C (daratumumab, lenalidomide, dexamethasone) · Active comparator
- Enrollment
- 1,450 (estimated)
- Primary outcomes
- Consolidation overall survival
- Sponsor
- ECOG-ACRIN Cancer Research Group with National Cancer Institute (NCI)
- Start
- Feb 24, 2021
- Primary completion
- Dec 31, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04566328 · updated Aug 19, 2026